Last updated: May 18, 2026
The neurotrophin family
Several proteins called “neurotrophins” regulate neuron survival, growth, and connectivity:
- BDNF (Brain-Derived Neurotrophic Factor): Master regulator of synaptic plasticity
- NGF (Nerve Growth Factor): Survival and growth of cholinergic neurons
- NT-3, NT-4/5: Other neurotrophins with overlapping functions
- GDNF: Glial-derived; dopaminergic neuron survival
Cognitive peptides primarily work by upregulating these endogenous neurotrophic factors rather than acting directly on cognition.
BDNF — the cognitive master switch
BDNF binds TrkB receptors triggering:
- LTP (long-term potentiation) — the cellular mechanism of memory
- Dendritic spine growth — increased synaptic density
- Neurogenesis in hippocampus and certain other regions
- Neuronal survival under stress
BDNF declines with age, stress, depression, and neurodegenerative disease. Peptides that upregulate BDNF (Semax, Cerebrolysin, Dihexa) have measurable cognitive effects.
Semax and BDNF
Semax dramatically increases BDNF expression in hippocampus and cortex (animal models show 4-8x baseline within hours of intranasal administration). The cognitive effects in humans (improved memory, attention, executive function) are consistent with mechanism.
Cerebrolysin’s multi-target approach
Cerebrolysin is a mixture of low-MW peptides derived from porcine brain. Effects include:
- BDNF and NGF mimetic activity
- GDNF receptor activation
- Anti-apoptotic effects
- Reduced amyloid pathology in Alzheimer’s models
Approved in 40+ countries for stroke, TBI, vascular dementia, and Alzheimer’s.
Dihexa and synaptogenesis
Dihexa (N-hexanoic-Tyr-Ile-(6) amino hexanoic amide) is a synthetic angiotensin IV derivative. Mechanism:
- Hepatocyte growth factor (HGF)/c-Met receptor activation
- Dramatic synaptogenesis (new synapse formation) in mouse models
- Reported 10,000x more potent than BDNF for synaptic effects
Phase 1 human trials initiated. Effect sizes in animal models are extraordinary; human translation pending.
FGL and NCAM
FGL (FGL peptide, ENA-actigen) is a 15-amino-acid peptide derived from neural cell adhesion molecule (NCAM). Mimics NCAM signaling at synapses. Animal models show:
- Improved memory consolidation
- Enhanced synaptic plasticity
- Reduced age-related cognitive decline
Routes of administration
Brain delivery is the key challenge for cognitive peptides:
- Intranasal: Direct olfactory pathway to CNS, bypasses blood-brain barrier. Used for Semax, Selank.
- Subcutaneous/IM: Systemic exposure. Some peptides cross BBB; others don’t well.
- Oral/sublingual: Mostly poor bioavailability except for specific peptides (Dihexa is studied orally).
Realistic expectations
Cognitive peptides produce measurable effects on:
- Working memory and attention (within days to weeks)
- Long-term memory consolidation (over weeks)
- Executive function (over weeks to months)
- Mood and motivation (often noticed first)
Effect sizes are meaningful but smaller than pharmaceutical stimulants. Best results come from sustained protocols (3-4 weeks) rather than acute use.
How long until cognitive peptides work?<br />
Subjective effects often within hours (especially intranasal Semax). Measurable cognitive improvements typically take 1-3 weeks of consistent use.
Can cognitive peptides reverse Alzheimer’s?<br />
Cerebrolysin shows symptom-slowing effects in mild-moderate Alzheimer’s in published trials. Reversal of established disease is not demonstrated.
Are these safer than ADHD medications?<br />
Different mechanisms entirely. Stimulants directly increase dopamine/norepinephrine signaling. Cognitive peptides work through neurotrophic pathways. Generally cleaner side effect profiles but smaller acute effects.
Can children use cognitive peptides?<br />
Most are not studied in pediatric populations. Cerebrolysin has pediatric clinical use in some countries for autism, ADHD, and developmental delay.